We are live on ! Find out more
TXG icon

10x Genomics

324 hedge funds and large institutions have $2.01B invested in 10x Genomics in 2025 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 106 increasing their positions, 99 reducing their positions, and 57 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more call options, than puts

Call options by funds: $5.72M | Put options by funds: $2.61M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

2% more funds holding

Funds holding: 319 → 324 (+5)

7% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 99

4% more capital inflows, than outflows

Capital inflows: $261M | Capital outflows: $251M

5% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 57

1.56% less ownership

Funds ownership: 107.49% → 105.93% (-1.6%)

Holders
324
Holders Change
+5
Holders Change %
+1.57%
% of All Funds
3.9%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
54
Increased
106
Reduced
99
Closed
57
Calls
$5.72​M
Puts
$2.61​M
Net Calls
+$3.11​M
Net Calls Change
-⁠$50​K

TXG Hedge Fund Activity: Q4 2025 in Review

324 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2025, worth a combined $2.01B — up 40% from $1.44B a quarter earlier.

Sellers outnumbered buyers: 57 funds closed out of TXG and 54 opened new positions — a net loss of 3 holders — while 99 trimmed existing stakes and 106 added.

The largest buyer was Fidelity Investments, adding an estimated $52.3M. The largest seller was Millennium Management, cutting an estimated $63.4M.

  • 324 institutional investors held 10x Genomics (TXG) as of Q4 2025, up from 319 in Q3 2025.
  • Funds reported $2.01B of 10x Genomics stock for Q4 2025, up 40% quarter-over-quarter.
  • 54 funds opened new 10x Genomics positions in Q4 2025 and 57 closed out, a net change of -3 holders.
  • The largest 10x Genomics buyer in Q4 2025 was Fidelity Investments, an estimated $52.3M added.
  • The largest 10x Genomics seller in Q4 2025 was Millennium Management, an estimated $63.4M sold.

Based on aggregated 13F filings for Q4 2025.